Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucab
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5
New Highs for Dow Transports: Top 3 Stocks Driving the Surge
08:30am, Wednesday, 04'th Dec 2024
The Dow Jones Transportation Average rose more than 8.4% in November to set a new high. Most components saw gains, with only two moving lower.
Clinical trials for HEMO-CAR-T: What's next? ICYMI
04:02am, Saturday, 30'th Nov 2024
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr.Vladislav Sandler and non-executive director Peter Redmond talked with Proactive about key developments, including its EGM. Redmond explain
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company's rationale for incorporating DNas
AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
12:16am, Thursday, 21'st Nov 2024
Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company's Obe-cel family and oncology pipeline include multi
Of 63 Fortune 500 Industry Leaders, 57 Pay Dividends, 38 Are Cash Rich And 1 Is A Buy
04:05pm, Wednesday, 20'th Nov 2024
AT&T, Altria Group, and Energy Transfer are top buys with dividends from $1K invested exceeding single share prices, meeting the dogcatcher ideal. Analysts forecast 15.47% to 28.33% net gains by Novem
MOTORTREND NAMES MERCEDES-BENZ E-CLASS 2025 CAR OF THE YEAR
08:00am, Wednesday, 20'th Nov 2024
– Mercedes-Benz's elegant midsize luxury car has outdone its competitors to secure MotorTrend's Golden Calipers for the second time in five years – LOS ANGELES , Nov. 20, 2024 /PRNewswire/ -- M
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
01:24pm, Monday, 18'th Nov 2024
Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process f
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
08:20am, Monday, 18'th Nov 2024
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
09:00am, Thursday, 14'th Nov 2024
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclini
Avis Budget Stock Appreciates 12% Despite Earnings Miss in Q3
09:40am, Monday, 11'th Nov 2024
CAR's third-quarter 2024 top line witnesses a decline due to a fall in revenues from the Americas.
Novel H 2 CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies
